About US
Contact us
-
Xs and Zs become popular in drug namesDrug names starting with an X or a Z may be hard to pronounce but that is really the last thing that drugmakers consider when coming up with new names. They want something that is memorable and evoke2013/1/28
-
Novartis has a win some, lose some day with GleevecNovartis and its cancer drug Gleevec had one of those days that starts off not looking so good and then something comes along to turn things around. It began Friday with the European Medicines Agen2013/1/28
-
New BMS drugs will fill yawning Plavix gap, CEO saysBristol-Myers Squibb's ($BMY) fourth-quarter sales are about as pure an example of generic erosion as we're likely to get. But the company's earnings rose, and newer drugs stepped up, deflecting atte2013/1/25
-
Amgen tops forecasts for Q4, thanks to new drugs and higher pricesAmgen ($AMGN) profits beat analyst expectations. And its sales grew by 11% in the fourth quarter. That's a feat, considering some of its biggest products--the anemia drugs Epogen and Aranesp--continu2013/1/25
-
Novartis braces for $3.5B hit to 2013 salesFlat sales and lower profits. These aren't predictions that shareholders like to hear. But like other Big Pharmas before it, Novartis ($NVS) faces generic competition for its biggest drugs. And like2013/1/24
-
Celgene's Abraxane shows promise in pancreatic cancerA drug that Celgene ($CELG) acquired in its $2.9 billion acquisition of Abraxis BioScience in 2010 is showing promise against the notoriously hard-to-treat pancreatic cancer. The disease kills 38,2013/1/24
-
FDA approval smooths way to more Botox salesWhile Botox still primarily springs to mind as a cosmetic treatment for wrinkles, the Allergan ($AGN) drug has been approved for 26 indications in 85 countries. The latest, and one it has been longin2013/1/23
-
Novo ready to rev up Tresiba for European launchNovo Nordisk ($NVO) is ready to roll with its new diabetes drug Tresiba--in Europe, at least. The company won regulatory approval for the potential blockbuster yesterday, setting up a mano-a-mano fig2013/1/23
-
Top pharmacists gather for conferenceA number of top independent pharmaceutical companies are set to gather for a conference this February in order to develop strategies that will enable progress in a radically changing health market.2013/1/22
-
BioChemics patents wound healing treatmentThe US Patent and Trademark office has issued a new patent for 'Methods and Compositions for Topical Treatment of Medical Conditions Including Wounds and Inflammation' on behalf of pharmaceutical firm2013/1/22